文章摘要
阿托伐他汀与依折麦布联合用药方案在急性冠脉综合征中的临床效果
  
DOI:
中文关键词: 阿托伐他汀  依折麦布  急性冠脉综合征  临床效果
英文关键词: Atorvastatin  Ezetimibe  Acute coronary syndrome  Clinical effect
基金项目:
作者单位
李成福 沈阳市辽中区骨伤科医院内科辽宁 沈阳 110200 
摘要点击次数: 168
全文下载次数: 0
中文摘要:
      目的:探究阿托伐他汀与依折麦布联合用药方案治疗急性冠脉综合征的临床效果。方法:选取2015年7月1日至2019年12月31日沈阳市辽中区骨伤科医院收治的82例急性冠脉综合征患者为研究对象,依据随机数字表法,随机将研究对象分为两组,对照组和观察组(每组41例),对照组采用阿托伐他汀治疗,观察组患者接受阿托伐他汀与依折麦布联合用药方案治疗,比较两组患者的血脂水平及不良反应发生率。结果:与对照组相比,观察组患者的TC、TG、LDL-C、HDL-C水平改善情况好,且不良反应发生率低,差异有统计学意义(P<0.05)。结论:给予急性冠脉综合征患者阿托伐他汀与依折麦布联合用药方案治疗,能有效降低患者血脂水平,且不良反应少,安全性高,值得借鉴。
英文摘要:
      Objective: To explore the clinical effect of Atorvastatin combined with Ezetimibe in the treatment of acute coronary syndrome(ACS). Methods: A total of 82 patients with ACS admitted to Liaozhong District Orthopedic and Traumatology Hospital from July 1, 2015 to December 31, 2019 were selected as the research objects. According to the random number table method, the subjects were randomly divided into two groups - the control group and the observation group (41 cases in each group). The control group was treated with Atorvastatin, and the observation group was treated with Atorvastatin and Ezetimibe. The blood lipid levels and the incidence of adverse reactions were compared between the two groups. Results: Compared with the control group, the level of TC, TG, LDL-C and HDL-C in the observation group improved better, and the incidence of adverse reactions was lower, the difference was statistically significant (P<0.05). Conclusion: The combination of atorvastatin and ezetimibe in patients with ACS can effectively reduce the blood lipid level of patients with less adverse reactions and high safety, which is worthy of reference.
查看全文   查看/发表评论  下载PDF阅读器
关闭

扫码关注本刊微信公众号“健康动向”